Result of AGM

RNS Number : 3565D

Futura Medical PLC

28 June 2021

 

28 June 2021

Futura Medical Announces Results Annual General Meeting

Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, today announces that at its Annual General Meeting, held today at 10:00am BST, all resolutions were duly passed by the shareholders.

The total number of votes received on each resolution were as follows:

Resolution		Voting fori	%	Voting against	%	Total votes	% ISC Voted	Votes withheldii
1	To receive and adopt the annual report of the directors and the financial statements for the financial year ended 31 December 2020 and the report of the appointed auditors thereon.	103,106,198	94.7	5,772,128	5.3	108,878,326	37.9	32,500
2	To re-elect Angela Hildreth as a Director of the Company, who retires by rotation in accordance with the Company's articles of association.	108,487,634	99.8	252,134	0.2	108,739,768	37.9	149,058
3	To re-appoint Grant Thornton UK LLP as auditor of the Company to hold office until the conclusion of the next annual general meeting of the Company.	108,825,140	100.0	40,026	0.0	108,865,166	37.9	45,660
4	To authorise the Directors to determine the remuneration of Grant Thornton UK LLP as auditor of the Company.	108,767,186	100.0	51,332	0.0	108,818,518	37.9	92,308
5	To authorise the directors of the Company to issue and allot relevant securities (up to 1/3 of the existing issued share capital) pursuant to section 551 of the Companies Act 2006.	108,505,091	99.9	113,134	0.1	108,618,225	37.8	292,601
6	Disapplication of the pre-emption provision of section 561 of the Act in connection with an offer of equity securities by way of a Rights Issue or up to an aggregate nominal value of £28,707.00 iii	107,966,630	99.5	520,098	0.5	108,486,728	37.8	94,098
7	Disapplication of the pre-emption provision of section 561 of the Act in connection with an offer of equity securities to fund an acquisition or a capital transaction iii	108,066,930	99.6	481,396	0.4	108,548,326	37.8	32,500

ⁱ Where shareholders appointed the Chairman as their proxy with discretion as to voting, their votes were cast in favour of the resolution

ⁱ A vote withheld is not a vote in law and is not counted towards the votes cast "For" or "Against" a resolution.

ⁱ Special Resolution (75% majority required)

The total voting rights of the Company as at 10:00 am on 24 June 2021 (the time by which shareholders wanting to vote at the AGM were required to be entered on the register) was 287,070,971 ordinary shares of 0.2p each. The Company does not hold any shares in treasury

-ENDS-

For further information please contact:

Futura Medical plc

James Barder, Chief Executive

Angela Hildreth, Finance Director and COO

Email: [e-mail]  

Tel: [phone]

www.Futuramedical.com

Nominated Adviser and Sole Broker:

Liberum

Richard Lindley/ Euan Brown/ Kane Collings

Tel: [phone]

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile

Email: [e-mail]

Tel: [phone]

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® technology. Each DermaSys® formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimised for clinical efficacy, safety, administration and patient convenience. The products are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.  

MED3000 is Futura's topical gel formulation that is a breakthrough treatment for erectile dysfunction (ED) through a unique evaporative mode of action. Futura has conducted a Phase 3 study using MED3000 in ED, referred to as "FM57". This was a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study delivering highly statistically significant results compared to pre-treatment baseline, consistently meeting all co-primary endpoints of IIEF, SEP2 and SEP3 (internationally accepted clinical trial endpoints in ED) with over 60% of patients experiencing a clinically meaningful improvement in their ED.  MED3000 also begins to work immediately in some patients, with 60% of patients seeing onset of their erection within 10 minutes of application. MED3000 is CE marked in Europe and the UK as a clinically proven topical treatment for adult men with erectile dysfunction.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.  www.futuramedical.com

 

END

 

 

RAGUWUURAOUNUAR